Medela LLC
$63.1K 190 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Tonix Medicines, Inc.
Tonix Medicines, Inc. reported $63,252.85 across General Payments, Research, and Ownership to 1,107 physicians and teaching hospitals across 1,107 transactions.
- $63.3K Below-median payer
- All-tracks total
- 1,107 Above-median volume
- Transactions
- 1,107 Above-median reach
- Recipients
- +$22.0K
- General Payments vs PY2023
Tonix Medicines, Inc. reported $63,252.85 across all CMS Open Payments tracks (General + Research + Ownership) to 1,107 physicians and teaching hospitals in Program Year 2024 - ranking #1288 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $63,252.85, averaging $57.14 per recipient.
Tonix Medicines, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
11/100
Transaction volume
F
18/100
Physician reach
F
18/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tonix-medicines-inc Tonix Medicines, Inc.
$63.3K · #1288/1,925 · 0.0% industry · PY2024
- TOT $63.3K
- RANK #1288
- SHARE 0.0%
- TXN 1,107
- RCP 1,107
- CAT 2
- GEN $63.3K
- ΔGEN +$22.0K
- TOP1 7.3%
- PY 2024
Volume peers
Nearest volume peer: Medela LLC ($63.1K)
Tonix Medicines, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Tonix Medicines, Inc.'s CMS-reported General Payments increased by $22.0K (+53.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: TONIX MEDICINES, INC.PY2024: Tonix Medicines, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $41,223.47
- PY2024
- $63,252.85
What the Data Shows for Tonix Medicines, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Tonix Medicines, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $36.5K, accounting for 57.7% of this company's General Payments and 38 transactions.
General Payment Breakdown by Type
Tonix Medicines, Inc. made 2 types of general payments. "Honoraria" is the largest category at $36.5K, 57.7% of General Payments.
How Tonix Medicines, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $36.5K | 38 | 57.7% |
| Food and Beverage | $26.8K | 1,069 | 42.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,872.81 (20.4%) of $63,252.85 in this company's General Payments records across 284 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Tonix Medicines, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Stewart Tepper
$4,586.11 across 7 reported transactions
- 2
Laszlo Mechtler
$2,510.00 across 46 reported transactions
- 3
George Nissan
$2,256.14 across 12 reported transactions
- 4
Stephanie Nahas-Geiger
$1,777.95 across 4 reported transactions
- 5
Andrew Blumenfeld
$1,742.61 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Tonix Medicines, Inc. ranks #1288 of 1,925 by total payments (bottom 33% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,565 of 1,838 by HHI (bottom 15% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Vericel Corporation : $1.3M total payments, HHI 200
- Straumann USA LLC : $7.6M total payments, HHI 200
- Eclipse Technology Solutions Inc. : $47.7K total payments, HHI 199
- Koya Medical, Inc. : $37.7K total payments, HHI 199
- F. Hoffmann-La Roche AG : $2.5M total payments, HHI 198
- Optinose US, Inc. : $1.3M total payments, HHI 196
- Tonix Medicines, Inc. (this company) : $63.3K total payments, HHI 196
- Patterson Companies, Inc. : $1.7M total payments, HHI 194
- Amneal Pharmaceuticals LLC : $1.9M total payments, HHI 194
- Rock Medical Orthopedics, Inc. : $23.5K total payments, HHI 194
- ShockWave Medical, Inc : $6.8M total payments, HHI 193
- Almirall LLC : $396.1K total payments, HHI 189
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Tonix Medicines, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Tonix Medicines, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Tonix Medicines, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Dentium USA
$63.0K 38 recipients
Compare payment profiles
MIS Implants Technologies, Inc.
$62.9K 11 recipients
Compare payment profiles
Cardinal Health Inc
$62.6K 40 recipients
Compare payment profiles
Zambon USA Ltd.
$62.5K 99 recipients
Compare payment profiles
Carbofix Spine Inc
$62.5K 83 recipients
Compare payment profiles
Put this to use
Tonix Medicines, Inc. ranks #1288 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Tonix Medicines, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.